CAR T cells targeting CD146 and HER2 for advanced sarcomas
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a new type of immunotherapy where your own immune cells are modified to find and attack sarcoma cells that carry markers called CD146 or HER2. It is for people with advanced sarcoma who have already tried standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed sarcoma that has spread, come back, or is not responding to standard therapy.
- You are at least 12 years old and in reasonably good health (able to do light work or be up and about).
- Your tumor cells have the CD146 or HER2 marker (or a type of sarcoma known to have them).
- You have not had any prior CAR T-cell or gene-modified cell therapy.
- You are not pregnant or breastfeeding, and you agree to use effective birth control during and for a year after treatment.
- You have adequate organ function (heart, lungs, bone marrow, liver, kidneys) and no serious uncontrolled infections or health conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR T cells) for people with advanced or recurrent sarcoma, a type of cancer that starts in bones or soft tissues. The treatment aims to help your immune system fight the cancer more effectively.
This trial tests a new treatment that uses your own immune cells, modified to attack sarcoma cancer cells. It may help people with advanced or recurrent sarcoma who have not responded to other treatments.
This trial tests a combination of targeted radiation and special immune cells (CAR T cells) for children and young adults whose bone or soft tissue sarcoma has come back or not responded to standard treatments. The CAR T cells are made from your own blood cells and are designed to attack a protein called B7-H3 found on the sarcoma cells.
This Phase 1 study tests a personalized immune-cell treatment (HER2 CAR T cells) given with an immune “checkpoint” medicine (pembrolizumab or another checkpoint blocker) to shrink advanced HER2-positive sarcoma. It may help patients whose cancer is progressing or coming back after prior treatment.
This trial tests a new kind of cell therapy called CAR T-cells that are engineered to find and attack sarcoma cells carrying a marker called B7-H3. It is for children and young adults whose sarcoma has come back or not gone away after treatment.
This trial tests an experimental cell therapy (CAR T-cells) for people with advanced pancreatic cancer, sarcoma, or breast cancer that has not responded to standard treatments. It may be an option if you have tried other therapies and are looking for a new approach.
Hear when a new Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.